Xintela AB (publ) (STO:XINT)

Market Cap	359.53M
Revenue (ttm)	4.22M
Net Income (ttm)	-39.19M
Shares Out	665.80M
EPS (ttm)	-0.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	321,022
Average Volume	546,655
Open	0.545
Previous Close	0.545
Day's Range	0.530 - 0.555
52-Week Range	0.204 - 0.700
Beta	1.94
RSI	65.02
Earnings Date	Feb 28, 2025

About Xintela AB

Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company’s stem cell products include XSTEM that is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indications; and EQSTEM, which is in preclinical development for the treatment of joint disease in horses. It is also developing antibody-based cancer therapies,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 21
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: XINT

Financial Performance

In 2024, Xintela AB's revenue was 4.22 million, an increase of 5303.85% compared to the previous year's 78,000. Losses were -39.19 million, -27.54% less than in 2023.